Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: A randomized, double-blind, placebo- controlled multicenter trial

Clinical Infectious Diseases

Volumn 26, Issue 3, 1998, Pages 611-619

  Oldfield III, Edward C ^a   Jeffrey Fessel, W ^b   Dunne, Michael W ^b   Dickinson, Gordon ^b   Wallace, Mark R ^b   Byrne, William ^b   Chung, Raymond ^b   Wagner, Kenneth F ^b   Paparello, Scott F ^b   Craig, Daniel B ^b   Melcher, Gregory ^b   Zajdowicz, Margan ^b   Williams, Richard F ^b   Kelly, J William ^b   Zelasky, Michael ^b   Heifets, Leonid B ^b   Berman, Jonathan D ^b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; AZITHROMYCIN; CLARITHROMYCIN; COTRIMOXAZOLE; DAPSONE; DIDANOSINE; PENTAMIDINE; PLACEBO; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; AIDS RELATED COMPLEX; ARTICLE; BACTERIUM ISOLATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HELPER CELL; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; PNEUMOCYSTOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RETROVIRUS INFECTION; SURVIVAL RATE;

EID: 6844240872     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514566     Document Type: Article

References (26)

1. Benson CA. Disease due to the Mycobacterium avium complex in patients with AIDS: epidemiology and clinical syndrome. Clin Infect Dis 1994; 18(suppl 3):S218-22.
2. Nightingale SD, Byrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency vims-positive patients. J Infect Dis 1992;165:1082-5.
3. Chin DP, Reingold AL, Stone EN, et al. The impact of Mycobacterium avium complex bacteremia and its treatment on survival of AIDS patients - a prospective study. J Infect Dis 1994;170:578-84.
4. Horsburgh CR, Havlik JA, Ellis DA, et al. Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy. Am Rev Respir Dis 1991;144:557-9.
5. Jacobson MA, Hopewell PC, Yajko DM, et al. Natural history of disseminated Mycobacterium avium complex infection in AIDS. J Infect Dis 1991;164:994-8.
6. Sathes S, Gascon P, Lo W, Pinto R, Reichman LB. Severe anemia is an important negative predictor for survival with disseminated Mycobacterium avium-intracellulare in acquired immunodeficiency syndrome. Am Rev Respir Dis 1990;142:1306-12.
7. Selik RM, Chu SY, Ward JW. Trends in infectious diseases and cancers among persons dying of HIV infection in the United States from 1987 to 1992. Ann Intern Med 1995;123:933-6.
8. Ives DV, Davis RB, Currier JS. Impact of clarithromycin and azithromycin on patterns of treatment and survival among AIDS patients with disseminated Mycobacterium avium complex. AIDS 1995;9:261-6.
9. Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993;329:828-33.
10. Masur H, the Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium. avium Complex. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus, N Engl J Med 1993;329:898-904.
11. Peters DH, Friedel HA, McTavish D. Azithromycin: a review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992;44:750-99.
12. Inderlied CB, Kolonoski PT, Wu M, Young LS. In vitro and in vivo activity of azithromycin (CP 62,993) against the Mycobacterium avium complex. J Infect Dis 1989;159:994-7.
13. Wildfeuer A, Laufen H, Zimmerman T. Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions. Antimicrob Agents Chemother 1996;40:75-9.
14. Young LS, Wiviott L, Wu M, Kolonoski P, Bolan R, Inderlied CB. Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS. Lancet 1991;338:1107-9.
15. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin or both. N Engl J Med 1996;335:392-8.
16. Heifets LB, Lindholm-Levy PJ, Comstock RD. Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium. Am Rev Respir Dis 1992;145:856-8.
17. Benson CA, Cohn DL, Williams P, ACTG 196/CPCRA 009 Study Team. A phase III prospective, randomized, double-blind study of the safety and efficacy of clarithromycin vs. rifabutin vs. clarithromycin plus rifabutin for prevention of Mycobacterium avium complex disease in HIV+ patients with CD4 counts less than or equal to 100 cells/μL [abstract no. 205]. In: Program and abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections (Washington, D.C.). Alexandria, Virginia: Infectious Diseases Society of America 1996:91.
18. Weltman AC, Righi SP, DiFerdinando GT, et al. Rifampicin-resistant Mycobacterium tuberculosis. Lancet 1995;345:1513.
19. Kaplan JE, Masur H, Holmes KK, eds. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1997; 46(RR-12):1-46.
20. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996;335:384-90.
21. Heifets L, Mor N, Vanderkolk J. Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrob Agents Chemother 1993;37:2364-70.
22. Kemper CA, Havlir D, Bartok AE, et al. Transient bacteremia due to Mycobacterium avium complex in patients with AIDS. J Infect Dis 1994;170:488-93.
23. Dunne MW, Havlir D, Dube M, et al. Prevention of Pneumocystis carinii pneumonia with azithromycin [abstract no. TU.B.410]. In: Program and abstracts of the 11th International Conference on AIDS (Vancouver). 1995.
24. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 1991; 91(suppl 3A):40S-5S.
25. Bowler WA, Hostettler C, Samuelson D, Lavin BS, Oldfield EC. Gastrointestinal side effects of intravenous erythromycin: incidence and reduction with prolonged infusion time and glycopyrrolate pretreatment. Am J Med 1992;92:249-53.
26. Wallace MR, Miller LK, Nguyen M-T, Shields AR. Ototoxicity with azithromycin. Lancet 1994;343:241.